Maralixibat
Alagille Syndrome
Mirum Pharmaceuticals, Inc.Small moleculePhase 2Active
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 58/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Alagille Syndrome cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
ATORVASTATIN Children's Hospital of Fudan University | Phase 4 | BB |
ODEVIXIBAT Albireo | Phase 1 | CCC |
Questran Albireo | Phase 1 | CC |
[14c]-a4250 Albireo | Phase 1 | CC |
Cholestyramine Albireo | Phase 1 | CC |
Same molecule, other indications
Maralixibat is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →